Abstract:Abstract Pediatric cancer patients are commonly profiled with gene-panel sequencing tests that yield few actionable results, in part due to the complex genomic alterations that define these malignancies. We hypothesized that integration of whole-genome (WGS) and RNA sequencing (RNAseq), would lead to a more comprehensive understanding of these diseases. Our study is uniquely focused on metastatic and relapsed disease, whereas previous studies focused on primary cases. We also prioritized longitudinal profiling, including with deep sequencing, to capture tumor evolution across primary and metastatic sites and to quantify the utility of resampling. We assembled a cohort of 219 high-risk pediatric oncology patients, including solid tumors, CNS tumors, leukemias/lymphomas, patients with relapsed/refractory disease (75), metastatic disease at diagnosis (7), rare diagnoses (17), prior cancer history, and estimated overall survival <50%. We characterized 286 samples with WGS (tumor ~60X; germline ~30X) and/or RNAseq (polyA selected, ≥20 million reads), including 95 samples taken from 44 patients at different time points (diagnosis, relapse, etc.). Variants, structural rearrangements, mutational signatures, and copy-number alterations were identified using WGS. RNAseq was used to profile gene expression outliers, gene fusions, and expression of variants. Integrated results were used to prioritize potentially actionable variants. For 20 patients (44 samples), we performed targeted deep sequencing of the DNA (~500X). RNAseq identified potentially druggable outlier gene expression and fusions, including 102 novel fusions where the 3’ gene is overexpressed. WGS identified aneuploidy, loss of heterozygosity and whole genome duplication across histotypes. Mutational burden and mutational signatures analyses identified profound effects from platinum drugs on tumor evolution, but treatment effects were not universal. Multiple sampling per patient uncovered drastic spatial and temporal differences in the genomes and transcriptomes of these tumors. Custom deep sequencing confirmed these findings, captured evolution missed by WGS, and furthered our understanding of the complex impacts of treatment on clonal evolution. Histotypes differed by whether actionability was higher for WGS or RNAseq alone, but in 66% of samples modality integration increased actionability. Integration also identified a subset of tumors that may be amenable to immunotherapy, but which lack canonical markers of response. Longitudinal analysis highlighted both the opportunities and risks of targeted therapy, with targetable variants gained and lost between timepoints. Our study shows that integrated multi-modality sequencing can elucidate novel insights into the biology of pediatric cancers and identify potential therapeutic targets not detected using gene-panel testing alone. Citation Format: Henry J. Martell, Avanthi T. Shah, Alex G. Lee, Stanley G. Leung, Soo-Jin Cho, María Pons Ventura, Ana Golla, Amanda E. Marinoff, Elizabeth P. Young, Bogdan Tanasa, Inge Behroozfard, Heng-Yi Liu, Aviv Spillinger, Michelle L. Turski, Nicole Elzie-Tuttle, Carlos Espinosa-Mendez, Arun Rangaswami, Tabitha M. Cooney, Cassie Kline, Anurag Agrawal, Jennifer Michlisch, Elliot Stieglitz, Mignon Loh, Amit J. Sabnis, Kieuhoa T. Vo, Sheri Spunt, Norman Lacayo, Holly C. Beal, Florette K. Hazard, Sophie Salama, David Haussler, Olena M. Vaske, Marcus R. Breese, E. Alejandro Sweet-Cordero. Integrative longitudinal genomic analysis of therapy-resistant and metastatic pediatric cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1759.

Abstract 5721: Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival

Abstract 3892: Systematic generation of a clinicogenomic harmonized oncologic real-world dataset (MSK-CHORD)

Automated real-world data integration improves cancer outcome prediction

Abstract 5222: AI-driven, mIF-based cell-omics reveals spatially resolved cell signature for outcome prediction in NSCLC patients

Abstract 2750: Leveraging machine-learning approaches to dissect drivers of clinical metastatic dynamics in lung adenocarcinoma

Abstract 4966: Machine learning and large language model approach to pancancer data elements

Abstract 2146: A quantitative in vivo pharmacogenomics platform uncovers biomarkers of therapy response

Abstract 1148: Multimodal spatial transcriptomics and proteomics analysis of the resectable NSCLC ecosystem following neoadjuvant chemoimmunotherapy

Abstract LB071: A phenomics platform combining imaging and artificial intelligence for rapid validation and advancement of novel oncology targets

Abstract 2551: Harness the power of real-world-data for oncology target and biomarker research: A case study by applying clinic-genomics data for 2,659 lung cancer patients and beyond

Abstract 6189: Deep-learning model trained on multiplex immunofluorescence-stained tissue samples predicts the survival of patients with non-small cell lung cancer better than PD-L1 TPS alone

Abstract 3517: Multi-modal single-cell and spatial genomics reveals genomic, adaptive and microenvironmental features of human non-small cell lung cancer brain metastasis

Abstract 970: Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA comprehensive genomic profiling

Abstract 6606: Biomarker discovery in non-small-cell lung cancer enabled by deep multi-omics profiling of proteins, metabolites, transcripts, and genes in blood

Abstract 6459: Molecular profiling of advanced non-small cell lung cancer in response to first-line immune checkpoint inhibitors and/or chemotherapy using multimodal real-world data

Abstract 2315: AI-enabled precision oncology era: Advanced and interactive interpretation of next-gneneration sequencing (NGS) reports

Abstract 5113: Liquid biopsy-based multiomics profiling using low-pass whole genome sequencing and proteomics with computational modeling reveals molecular correlates of disease severity in EGFR/ALK wild type NSCLC patients

Abstract 4951: Integrative multi-omic machine learning model predicts neoadjuvant immunotherapy response using molecular data and deep learning-derived features from digital pathology

Abstract B066: An AI approach to unraveling treatment response in pancreatic cancer: Insights from the COMPASS trial leveraging large language models (LLMs)

Abstract 1759: Integrative longitudinal genomic analysis of therapy-resistant and metastatic pediatric cancers

Abstract 963: Comprehensive epigenomic profiling from plasma to inform therapy selection: A proof-of-concept study in cancer